STOCKHOLM , SE / ACCESS Newswire / November 2, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the following upcoming healthcare conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Location: InterContinental Boston , Boston Format : Fireside chat and 1×1 meetings Date and time: Monday, November 9, 2026 , 8:00-8:25 AM ET Participant: Ahmed Mousa , Chief Executive Officer Webcast: Link Stifel 2026 Healthcare Conference Location: Lotte New York Palace , New York Format : Presentation and 1×1 meetings Date and time: Thursday, November 12, 2026 , 10:40-11:10 AM ET Participant: Ahmed Mousa , Chief Executive Officer Webcast: Link For further information, please contact: Hans Jeppsson , Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com About Vicore Pharma Holding AB Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com Attachments Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.